Development of manufacturing technology with clinical evaluation of new absorption-base dressings based on the collagen database for healing treatments of different aetiology. (Q78533): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item: Fixing rounding issue)
(‎Removed claim: summary (P836): The aim of the project is to develop manufacturing technologies with clinical evaluation of new dressings for treatment with different aetiology wounds.As a result of the project, the applicant plans to place on the market 2 types of absorbent dressings based on bio-active collagen derived from fish origin.The product innovation introduced by the various forms of dressing will make it logical, flexible and easy to apply, with a system of adver...)
Property / summary
The aim of the project is to develop manufacturing technologies with clinical evaluation of new dressings for treatment with different aetiology wounds.As a result of the project, the applicant plans to place on the market 2 types of absorbent dressings based on bio-active collagen derived from fish origin.The product innovation introduced by the various forms of dressing will make it logical, flexible and easy to apply, with a system of adversarial proceedings in the various phases of healing.The objective will be achieved by the implementation of industrial research (ETAPY I and II), which includes the development of a method of producing the physical form of dressings and the sterilisation of dressings, while maintaining the structure of the alpha-helitic bioactively concerned exogenous biogel.In the framework of development work (ETAP III), clinical trials will be carried out to confirm the initial assumptions for reducing the treatment time for chronic wounds.Phase IV is the pre-implementation work on the preparation for registration, patenting and preparation for commercialisation in the demanding pharmaceutical products market.According to AM information from the MA of the OP IR, the MA of the OP IR would ask you to enter the reference number and the articles on aid in the field “Summary of the project” in SL2014 by shortening the description of the project (the arbitrary decision? what is being discarded from this description in order to find Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (Dz.(OJ L(OJ L 187/1, 26.06.2014)). (English)
 
Property / summary: The aim of the project is to develop manufacturing technologies with clinical evaluation of new dressings for treatment with different aetiology wounds.As a result of the project, the applicant plans to place on the market 2 types of absorbent dressings based on bio-active collagen derived from fish origin.The product innovation introduced by the various forms of dressing will make it logical, flexible and easy to apply, with a system of adversarial proceedings in the various phases of healing.The objective will be achieved by the implementation of industrial research (ETAPY I and II), which includes the development of a method of producing the physical form of dressings and the sterilisation of dressings, while maintaining the structure of the alpha-helitic bioactively concerned exogenous biogel.In the framework of development work (ETAP III), clinical trials will be carried out to confirm the initial assumptions for reducing the treatment time for chronic wounds.Phase IV is the pre-implementation work on the preparation for registration, patenting and preparation for commercialisation in the demanding pharmaceutical products market.According to AM information from the MA of the OP IR, the MA of the OP IR would ask you to enter the reference number and the articles on aid in the field “Summary of the project” in SL2014 by shortening the description of the project (the arbitrary decision? what is being discarded from this description in order to find Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (Dz.(OJ L(OJ L 187/1, 26.06.2014)). (English) / rank
Normal rank
 

Revision as of 12:51, 14 October 2020

Project in Poland financed by DG Regio
Language Label Description Also known as
English
Development of manufacturing technology with clinical evaluation of new absorption-base dressings based on the collagen database for healing treatments of different aetiology.
Project in Poland financed by DG Regio

    Statements

    country
    Poland
    0 references
    EU contribution
    2,115,173.32 zloty
    0 references
    507,641.60 Euro
    exchange rate to Euro
    0.24 Euro
    point in time
    13 January 2020
    0 references
    budget
    2,966,310.42 zloty
    0 references
    711,914.50 Euro
    exchange rate to Euro
    0.24 Euro
    point in time
    13 January 2020
    0 references
    co-financing rate
    71.31 percent
    0 references
    start time
    1 March 2019
    0 references
    end time
    31 August 2022
    0 references
    beneficiary name (string)
    REGIONALNE CENTRUM ZDROWIA SP. Z O.O.
    0 references
    beneficiary
    Q2510387
    0 references
    coordinate location

    52°15'0.4"N, 15°55'15.2"E
    0 references
    summary
    Celem projektu jest opracowanie technologii wytwarzania wraz z oceną kliniczną nowych opatrunków do leczenia ran o różnej etiologii. W wyniku realizacji projektu Wnioskodawca planuje wprowadzenie do obrotu 2 rodzajów wchłanialnych opatrunków na bazie bioaktywnego kolagenu pochodzenia rybiego. Wprowadzona innowacja produktowa dzięki różnym formom opatrunku umożliwi w sposób logiczny, elastyczny i łatwy do zastosowania system postępowania z raną w różnych fazach gojenia. Cel zostanie osiągnięty przez realizację badań przemysłowych (ETAPY I i II) obejmujących opracowanie metody wytworzenia fizycznej postaci opatrunków oraz sterylizacji opatrunków z zachowaniem struktury alfa-helitycznej bioaktywnego tropokolagenu egzogennego. W ramach prac rozwojowych (ETAP III) zostaną przeprowadzone badania kliniczne, które mają potwierdzić osiągnięcie początkowych założeń dotyczących skrócenia czasu leczenia ran przewlekłych. Etap IV to prace przedwdrożeniowe dotyczące przygotowania do rejestracji, patentowania rozwiązań oraz przygotowania do komercjalizacji na wymagającym rynku wyrobów farmaceutycznych. Zgodnie z informacją z AM IZ PO IR, prośba, żeby wpisać nr referencyjny i artykuły dot. pomocy w polu „Krótki opis projektu” w SL2014 poprzez skrócenie opisu projektu, (decyzja arbitralna Wasza co wyrzucić z tego opisu, żeby się znalazło sformułowanie art. 25 rozporządzenia KE nr 651/2014 z dnia 17 czerwca 2014 r. uznające niektóre rodzaje pomocy za zgodne z rynkiem wewnętrznym w stosowaniu art. 107 i 108 Traktatu (Dz. Urz. UE L 187/1 z 26.06.2014)). (Polish)
    0 references

    Identifiers

    Polish Kohesio ID
    POIR.01.01.01-00-1004/18
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q78533&oldid=6343022"